H.I.G. Capital Acquires ITH Group Limited to Boost UK Pharmaceutical Services
On June 9, 2025, H.I.G. Capital, a prominent global alternative investment firm managing $70 billion in capital, made headlines with the acquisition of ITH Group Limited. This strategic move marks a significant commitment to the UK pharmaceutical sector, particularly in the realm of aseptic compounding services.
ITH Group, founded in 2008 and based in London, is recognized as a leading provider of specialized injectable medications tailored for patients with unique medical needs that standard treatments cannot address. The company has established a strong reputation in the industry, focusing on critical areas such as chemotherapy, total parenteral nutrition, and central intravenous additive services. Its capabilities extend beyond just compounding, as ITH also operates a digital pharmacy that supplies essential licensed medications to private healthcare providers and the National Health Service (NHS).
Financial terms of the acquisition were not disclosed, but H.I.G. aims to uphold ITH's legacy of organic growth while simultaneously pursuing new initiatives. Notably, these initiatives include enhancing production capacity, reinforcing the company’s ability to meet the growing demand for compounded medications across both public and private sectors.
Adam Bloom, the CEO of ITH Group, expressed enthusiasm about the partnership, stating, "I am delighted to welcome H.I.G. as a key investor in the ITH Group. Since our inception, we’ve focused on investing in our people and improving the services we offer our patients. Today, we are proud to be a leading provider of compounding services in the UK, supporting both the NHS and private healthcare sectors." Bloom emphasized the commitment to expanding service offerings and advancing expertise in supplying critical compounded medicines.
H.I.G. Capital has a history of supporting its portfolio companies with a focus on growth and operational improvement. John Harper, Managing Director and Head of H.I.G.'s Europe Lower Middle Market LBO team in London, remarked, "We are thrilled to support Adam, Karen, and their team in further building upon ITH's success. The company’s reliable provision of compounded pharmaceuticals to both NHS and private customers positions it uniquely in what is seen as an undersupplied market."
The prior existing management team of ITH will remain intact, with both Bloom and Karen Hamling continuing their roles as CEO and COO, respectively. Their leadership will be pivotal as the company embarks on this new chapter of growth following the acquisition.
Gordon Cameron, the non-executive Chairman of ITH, praised the achievements of the management team, noting that they have created a business that delivers critical services to a vital sector of the UK health landscape. He remarked, "The company has built a reputation for reliability through its unwavering focus on high-quality customer service. I am excited to join the business and to support H.I.G. in driving ITH's growth."
Overall, this acquisition not only enhances H.I.G.’s investment portfolio but also strengthens ITH Group and its mission to provide essential compounded medications to those who need them the most. As economic and healthcare landscapes evolve, this partnership is set to have a lasting impact on the UK pharmaceutical industry.
For those curious about ITH’s comprehensive services or interested in their innovative approach to healthcare, further information can be found on their official website, ithgroup.uk. This acquisition stands as a testament to H.I.G. Capital’s strategic foresight in the healthcare investment sector and its commitment to improving patient outcomes through enhanced pharmaceutical services.
ITH Group, founded in 2008 and based in London, is recognized as a leading provider of specialized injectable medications tailored for patients with unique medical needs that standard treatments cannot address. The company has established a strong reputation in the industry, focusing on critical areas such as chemotherapy, total parenteral nutrition, and central intravenous additive services. Its capabilities extend beyond just compounding, as ITH also operates a digital pharmacy that supplies essential licensed medications to private healthcare providers and the National Health Service (NHS).
Financial terms of the acquisition were not disclosed, but H.I.G. aims to uphold ITH's legacy of organic growth while simultaneously pursuing new initiatives. Notably, these initiatives include enhancing production capacity, reinforcing the company’s ability to meet the growing demand for compounded medications across both public and private sectors.
Adam Bloom, the CEO of ITH Group, expressed enthusiasm about the partnership, stating, "I am delighted to welcome H.I.G. as a key investor in the ITH Group. Since our inception, we’ve focused on investing in our people and improving the services we offer our patients. Today, we are proud to be a leading provider of compounding services in the UK, supporting both the NHS and private healthcare sectors." Bloom emphasized the commitment to expanding service offerings and advancing expertise in supplying critical compounded medicines.
H.I.G. Capital has a history of supporting its portfolio companies with a focus on growth and operational improvement. John Harper, Managing Director and Head of H.I.G.'s Europe Lower Middle Market LBO team in London, remarked, "We are thrilled to support Adam, Karen, and their team in further building upon ITH's success. The company’s reliable provision of compounded pharmaceuticals to both NHS and private customers positions it uniquely in what is seen as an undersupplied market."
The prior existing management team of ITH will remain intact, with both Bloom and Karen Hamling continuing their roles as CEO and COO, respectively. Their leadership will be pivotal as the company embarks on this new chapter of growth following the acquisition.
Gordon Cameron, the non-executive Chairman of ITH, praised the achievements of the management team, noting that they have created a business that delivers critical services to a vital sector of the UK health landscape. He remarked, "The company has built a reputation for reliability through its unwavering focus on high-quality customer service. I am excited to join the business and to support H.I.G. in driving ITH's growth."
Overall, this acquisition not only enhances H.I.G.’s investment portfolio but also strengthens ITH Group and its mission to provide essential compounded medications to those who need them the most. As economic and healthcare landscapes evolve, this partnership is set to have a lasting impact on the UK pharmaceutical industry.
For those curious about ITH’s comprehensive services or interested in their innovative approach to healthcare, further information can be found on their official website, ithgroup.uk. This acquisition stands as a testament to H.I.G. Capital’s strategic foresight in the healthcare investment sector and its commitment to improving patient outcomes through enhanced pharmaceutical services.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.